Lundbeck to acquire US-based Abide Therapeutics for up to $400m

This article was originally published here

Headquartered in California, Abide has developed a platform to discover potent and selective serine hydrolase inhibitors. The platform is used by the company to identify, develop, and validate

The post Lundbeck to acquire US-based Abide Therapeutics for up to $400m appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply